Topics

Intensive Glycemic Control For Diabetic Foot Ulcer Healing

2020-04-01 04:26:52 | BioPortfolio

Summary

With the available molecular and cellular evidence of impaired wound healing due to hyperglycemia, investigators postulate hypothesis asking whether intensive glycemic control could improve diabetic foot ulcer healing rates. A study showed improvement in phagocytic activity of macrophages after 5 days of intensive glycemic improvement in 21 patients of diabetes. Another retrospective cohort study studied the effect on HbA1c as predictor of healing rate in DFU. Latter found significant association of HbA1c with wound area healing rate. However a recent systematic review failed to find any randomized control trial comparing the effect of intensive versus conventional glycemic control for treating DFU. Hence, investigators want to explore the hypothesis by conducting a randomized control trial with the primary aim of wound healing in patients of diabetic foot ulcer in response to intensive glycemic control in comparison to conventional glycemic management.

Description

BURDEN OF DIABETIC FOOT According to International Diabetic Federation, there will be over 642 million people with diabetes in the world by 2040.Diabetic Foot Ulcer (DFU) is one of the most serious, most costly and at times life threatening complication of diabetes. The lifetime incidence of foot ulcer occurrence in diabetes is up to 25%. Both prevalence and incidence of DFU is higher in developing countries due to multitude of factors like poverty, poor sanitation & hygiene, barefoot walking, lack of education, poor healthcare access.

DFU related morbidity and hospitalization has shown a meteoric rise. One study showed that 20% of admissions in patients of diabetes were due to DFU. 56%of ulcers become infected and 1 in 5 of these will requiresome level of amputation.In addition, it has been projected that 15% of diabetic foot ulcers result in lowerextremity amputations and 85% of diabetic patientswho undergo lower extremity amputations had an ulcerprior to amputation.The 5-year relative mortality afterdiabetic foot ulcer is 48%, second only to lung cancer.

Multiple risk factors have been attributed to the development of DFU including male gender, duration of diabetes >10 years, older age, diminished vision, peripheral vascular disease, high BMI, sensory neuropathy, retinopathy, nephropathy, HbA1c, foot deformity, high plantar pressures, poor foot care habits, barefoot walking etc. From DCCT there exists robust evidence that strict glycemic control can decrease all diabetic related complications. There are other studies demonstrating improvements in neuropathy and peripheral vascular disease as a result of strict glycemic control. However, there is no specific evidence/intervention for DFU prevention.

IMPAIRED WOUND HEALING IN DIABETES Wound healing is impaired in diabetes at multiple stages. The defects are observed at both cellular and molecular levels. Extrinsic factors like mechanical stress, trauma and ischemia negatively influence the healing process. Hyperglycemia itself has been shown to have deleterious effect on wound healing through formation of advanced glycation end products (AGEs) & reactive oxygen species (ROS) which induce the production of inflammatory molecules (TNF-α, IL-1) and interfere with collagen synthesis. There is interference in collagen synthesis due to increased expression of matrix metalloproteinases.

CHALLENGES WITH RESEARCH IN THIS AREA With the clinical benchmarks set by major trials like UKPDS, it is often difficult for clinicians to ethically conduct any study investigating the effects of intensive versus conventional glycemic control. Even on demonstrating the clinical benefit involving intensive glycemic control, it is a difficult task to recruit as well as follow up subjects. Many diabetic patients are frail and have multiple co-morbidities that render them incapable of following such interventions. Intensive glycemic control makes these individuals prone to the detrimental effects of hypoglycemia. In a trial investigating the effect of hyperglycemia and intensive glycemic control on DFU healing, the authors faced many challenges in recruiting and allocating the patients. This trial was completed without any results.

There is marked variation in the definition of intensive glycemic control between guidelines and trials.Most of the current glycemic targets for diabetes are based onseveral pioneering trials that investigated the effects of intensiveglycemic control compared to conventional treatments. Importantly, the beneficial effects on microvascular complicationsfrom using intensive glycemic control took more than five yearsto emerge, and the benefits were less pronounced for people withadvanced type 2 diabetes compared to those with new-onset type2 diabetes. Nevertheless, diabetic foot ulcer specific outcomes were not studied or neglected in these trials. Hence, the onus is on new investigators to study the outcomes in DFU through the prism of intensive glycemic control.

In many trials investigating intensive versus conventional glycemic control,lower limb amputation was an outcome measure. This outcome was not reported in relation to presentation with, development of, or healing of foot ulceration. Amputation was due to the ease of measurement and definitive nature of such a practical end-point. However, there are inconsistencies in the true estimation of amputation as an outcome. The UKPDS defined amputation as a major limbcomplication requiring lower limb amputation of a digit or anylimb for any reason and included digital amputations which areusually classified as minor amputations. A Cochrane review concluded that intensive glucose control reduced the risk of amputation by 36% in type 2 diabetes (RR 0.64, 95% CI: 0.43 to 0.95; 6960 participants ineight trials). However, this information was based on amputations defined in several ways (including both minor and major amputations). Although this data provides evidence to endorse the efficacy of intensive glycemic control in preventing amputations, its exact correlation to foot ulcer healing remains unanswered.It is a known fact that foot ulceration often precedes amputation, therefore, ulcer specific measures like time to ulcer healing, percent reduction in ulcer area, need to be measured as an outcome. From a patient and HRQoL point of view, foot ulcer healing can be seen as a beneficial outcome over a damaging endpoint like amputation.

In a meta-analysis of the six control arms ofwound-healing trials in patients with a neuropathic ulcer, 24% of the ulcers were healed at 12 weeks and only 31%at 20 weeks. But these data were likely influenced by selection bias, as the elderly patient with multiple co-morbidities is usually excluded from such trials, follow-up was short and treatment was suboptimal and non- EVIDENCE OFNEED FOR INTENSIVE GLYCEMIC CONTROL IN DFU Various studies highlighting the importance of hyperglycemia and glycemic control in diabetic foot ulcer healing are described below.

In a multi-center study, poor glycemic (blood glucose) control was evident in nearly half of the participants who had foot ulcers, with 49% having an HbA1c (glycemic measure) level above 8.4%.

In a retrospective cohort study of 183 diabetic patients conducted at the John Hopkins Wound Center, it was seen that HbA1c was an important clinical predictor of the rate of wound healing. The mean HbA1c was 8.0%. For each 1%-point increase in HbA1c level,the daily wound healing ratedecreased by 0.028 cm² per day (95% CI: 0.003 to 0.054). This was irrespective of presence of neuropathy (n=109), smoking status (n=121) and peripheral arterial disease (n=53). The study didn't throw any light on anti-diabetic treatment received by patients.

In another retrospective study of 63 diabetic patients conducted at a Midwestern outpatient wound care clinic in USA for 3 years, it was seen that the HbA1c values closest to ulcer closure ranged from 5.3 to12.3 (mean, 7.68 [SD, 1.81]). It was also found that patients with higher HbA1c levels did experience wound healing, but in a significantlylonger period than those with lower HbA1c. Approximately 80% of this sample (n = 50)had peripheral vascular disease, and more than 60% (n = 39) hadrenal disease. Here also the investigators didn't mention the anti-diabetic treatment being received by patients.

An Indian prospective study (over 2 years) has explored the concept of HbA1c as a predictor of healing rate in diabetic ulcers. 100 diabetic patients were equally divided into 2 groups with mean HbA1c levels of 6.50 ± 0.441 in Group A and Group B with the mean value of 10.40 ± 1.550. Subsequently, standard treatment protocols were followed, and mean reduction in ulcer area, length, and width were measured; a statistically significant difference was found in the mean area change per day between the two groups with P<0.0001. However, the study did not explore the effect of intensive glycemic treatment in the uncontrolled diabetic subgroup.

Investigators in Barcelona, Spain addressed the issue of impairment in phagocytic activity in relation to glycemic control and, whether or not this impairment could be reversible after improving blood glucose levels. In their case control study, 21 type 2 DM and 21 healthy volunteers were prospectively recruited. Baseline HbA1c was 8.78 ± 2.01 in T2DM patients whereas it was 5.79 ± 0.45 in healthy volunteers. Baseline FBG was 9.49 ± 3.15 in T2DM patients whereas it was 5.73 ± 0.83 in healthy volunteers. By use of flow cytometry they were able to deduce that Type 2 diabetic patients showed a lower percentage of activated macrophages in comparison with non-diabetic subjects (54.00618.93 vs 68.53612.77%; p = 0.006). Also,significant negative correlations between phagocytic activity and fastingglucose (r = 20.619, p = 0.004) and HbA1c (r = 20.506, p = 0.019) were detected. In their intervention study 12 previous T2DM patients were admitted and treated intensively (9-point blood glucose profile) for 5 days. In these patients who underwent metabolic optimization, a significant increase in phagocytic activitywas observed (p = 0.029). The investigators postulated that the reversibility of phagocytosis dysfunction after a short period of glycemic control may have been attributable not only to the normalization of the diabetic milieu but also to the effect of exogenous insulin.

Another prospective study conducted in Oregon, USA investigated whether different diabetic treatment regimens affect diabetic foot ulcer healing. In this study 85 patients were followed up for a period of 2 years. Insulin treatment was apart of diabetes management in 52 (61.2%) cases. Insulin therapy significantly increased thewound healing rate (30.3% [20/66 ulcers] vs. 9.8% [4/41 ulcers]) (p=0.013). In multivariaterandom-effect logistic regression model, adjusting for age, gender, smoking status, type of diabetes, hypertension, chronic kidney disease, peripheral arterial disease, oral hypoglycemic use, wound infection, involved side, presence of Charcot's deformity, gangrene, osteomyelitis on x-ray, and serum hemoglobin A1C levels, insulin treatment was associated with a higher chance of complete healing (beta±SE: 15.2±6.1, P=0.013).

In a Cochrane systematic review aimed to assess the effects of intensive glycemic control compared to conventional control on the treatment of foot ulcers in people with type 1 and type 2 diabetes. The authors searched for evidence in both published and unpublished material. They were unable to find any clinical trials which had successfully investigated the impact of intensive versus conventional glycemic control on foot ulcer outcomes. Investigators want to fill this lacuna by conducting a randomized control trial with the primary aim of wound healing in participants of diabetic foot ulcer on intensive glycemic control versus conventional treatment.

Study Design

Conditions

Diabetic Foot Ulcer

Intervention

Insulin Glargine, Diabetic DM

Location

Deptt of Endocrinology
Chandigarh
India
160012

Status

Not yet recruiting

Source

Postgraduate Institute of Medical Education and Research

Results (where available)

View Results

Links

Published on BioPortfolio: 2020-04-01T04:26:52-0400

Clinical Trials [4684 Associated Clinical Trials listed on BioPortfolio]

Evaluation of DIAMEL® Combined With Insulin in Diabetic Foot Ulcer

Diabetic foot syndrome is one of the most frequent complications in type 2 diabetic patients. The present work is carried out with the objective of evaluating the use of DIamel combined wi...

Intensive Versus Conventional Glycemic Control in Diabetic Foot Ulcer Healing

Diabetic foot ulcer is one of the most serious, most costly and at times life threatening complication of diabetes. The lifetime incidence of foot ulcer occurrence in diabetes is up to 25%...

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

This is a randomized, double-blind, placebo-controlled, sequential dose escalation study in diabetic subjects with a diabetic lower leg or foot ulcer. All subjects will receive standard-of...

Preventing Diabetic Foot Ulcers Through Cleaner Feet

Foot complications are among the most serious and costly complications of diabetes. People with diabetes have a 10-fold increased risk for a leg or foot amputation compared to those that d...

Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic Wounds

Type 1 and Type 2 diabetic patients with diabetic foot ulcer will be recruited and screened for participation in the study. Eligible patients will be randomized 1:1 to either experimental ...

PubMed Articles [3757 Associated PubMed Articles listed on BioPortfolio]

Infrared thermography and ulcer prevention in the high-risk diabetic foot: data from a single-blind multicentre controlled clinical trial.

To assess the usefulness of monthly thermography and standard foot care to reduce diabetic foot ulcer recurrence.

Rat bite as a cause of diabetic foot ulcer in sub-Saharan Africa.

There have been relatively few reports of foot ulcers in diabetes resulting from rat bite. The findings were derived from people attending a single specialist service in Dar es Salaam for diabetic foo...

Application of Topical Oxygen Therapy in Healing Dynamics of Diabetic Foot Ulcers - A Systematic Review.

Individuals with diabetes may develop diabetic foot ulcers due to diabetic peripheral neuropathy. Multiple factors influence the ulcer healing process; oxygen helps in facilitating the different stage...

Mortality in patients with diabetic foot ulcer: diabetic neuropathy is not innocent.

The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes.

Unilateral offloading footwear prescribed to patients with diabetic foot ulcers elevates one limb relative to the other, which may lead to limp and abnormal gait. This study investigated whether the u...

Medical and Biotech [MESH] Definitions

Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.

Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)

Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. It can be caused by the presence of INSULIN ANTIBODIES or the abnormalities in insulin receptors (RECEPTOR, INSULIN) on target cell surfaces. It is often associated with OBESITY; DIABETIC KETOACIDOSIS; INFECTION; and certain rare conditions. (from Stedman, 25th ed)

The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin.

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

More From BioPortfolio on "Intensive Glycemic Control For Diabetic Foot Ulcer Healing"

Quick Search

Relevant Topics

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...


Searches Linking to this Trial